Novartis AG (NVS)
| Market Cap | 315.80B +48.4% |
| Revenue (ttm) | 56.67B +9.6% |
| Net Income | 13.98B +17.1% |
| EPS | 7.15 +21.8% |
| Shares Out | 1.91B |
| PE Ratio | 23.69 |
| Forward PE | 18.71 |
| Dividend | $3.10 (1.83%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 2,079,085 |
| Open | 169.11 |
| Previous Close | 165.51 |
| Day's Range | 168.85 - 170.34 |
| 52-Week Range | 97.72 - 170.34 |
| Beta | 0.46 |
| Analysts | Hold |
| Price Target | 118.00 (-30.35%) |
| Earnings Date | Feb 4, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $118.0, which is a decrease of -30.35% from the latest price.
News
The immortal life of Henrietta Lacks lawsuits gets a bit shorter with Novartis settlement
Details of the agreement, which was finalized in federal court in Maryland this month, aren't public.
Novartis (NVS) Backs Atrium Therapeutics' Launch with $270M Funding
Novartis (NVS) Backs Atrium Therapeutics' Launch with $270M Funding
Novartis (NVS) Completes Acquisition of Avidity Biosciences
Novartis (NVS) Completes Acquisition of Avidity Biosciences
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
Adds Avidity's differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipeline Potentially unlocks multi-bill...
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
Basel, February 27, 2026 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending ma...
Novartis, Genentech file suit alleging illegal importation of prescription drug
Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine. The importation of the drug, which has strict shipping and...
Novartis picks Texas to build next radioligand therapy site
Novartis to build radioligand therapy site in Texas to expand US manufacturing
Novartis said on Wednesday it intends to build a radioligand therapy manufacturing site in Texas, expanding its U.S. footprint with what will be its first such facility in the state and fifth nationwi...
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
Novartis' business is resilient, as evidenced by its ability to grow sales despite a major patent cliff. The Swiss healthcare giant's income program is another great attraction for long-term investors...
Novartis: Pluvicto Shows Effectiveness In Real-world Studies
(RTTNews) - Novartis (NVS) said multiple US real-world studies reinforced earlier use of Pluvicto before chemotherapy in metastatic castration-resistant prostate cancer. Real-world use of Pluvicto res...
Novartis (NVS) Showcases New Rhapsido Data at AAAAI Meeting
Novartis (NVS) Showcases New Rhapsido Data at AAAAI Meeting
Novartis Presents 5 Key Abstracts Evaluating Rhapsido In CSU, Peanut Allergy At AAAAI Annual Meet
(RTTNews) - Novartis AG (NVS) Monday said that it will present data from five key abstracts evaluating Rhapsido, also known as Remibrutinib in chronic spontaneous urticaria or CSU and as an investigat...
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Basel, February 23, 2026 – Novartis will present data from five key abstracts evaluating the highly selective oral Bruton's tyrosine kinase inhibitor (BTKi) Rhapsido® (remibrutinib) in chronic spontan...
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades
Novartis is a large drugmaker with a wide-ranging portfolio. Like all drugmakers, it faces the challenge of patent expirations.
Novartis to exit listed Indian arm in Rs 1,446cr deal
India Business News: New Delhi: Swiss drug firm Novartis will sell its entire stake of nearly 71% in its listed Indian subsidiary for about Rs 1,446 crore to a clutch of p.
Novartis (NVS) Sells Majority Stake in Indian Subsidiary for $159 Million
Novartis (NVS) Sells Majority Stake in Indian Subsidiary for $159 Million
Trump Says Tariffs Drove Novartis' $23 Billion US Expansion
Trump Says Tariffs Drove Novartis' $23 Billion US Expansion
Novartis to Sell 70.68% Stake in India Unit for 14.46 Billion Rupees
Novartis to Sell 70.68% Stake in India Unit for 14.46 Billion Rupees
Trump says tariffs prompt Novartis to expand U.S. manufacturing
Novartis to sell 70.7% stake in Indian unit for $159M
Novartis India shares surge 14.65% today after Novartis AG to sell 70.68% stake
Friday, February 20: Shares of Novartis India Limited jumped sharply in early trade after its promoter, Novartis AG, agreed to...
Trump meets Novartis CEO, says drugmaker building 11 US plants
U.S. President Donald Trump said he met Vas Narasimhan, the chief executive officer of Swiss drugmaker Novartis , at the White House on Wednesday.
Novartis to sell entire 71% stake in Indian unit to consortium of WaveRise Investments
Swiss pharmaceutical firm Novartis said on Friday that it would sell its entire 70.68% stake in its listed Indian unit to a consortium of WaveRise Investments, ChrysCapital and Two Infinity Partners.
Biodexa Licenses Phase 1-Ready Drug Candidate From Otsuka For Rare Stomach Cancer
Zinger Key Point: MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical-stage bi...
Novartis Makes $1.8 Billion Bet On Oral Peptides
Novartis Makes $1.8 Billion Bet On Oral Peptides